{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:56:05Z","timestamp":1760230565980,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Heterologous vaccination regimens could contribute to broadening vaccination coverage. To date, there is little evidence on the effectiveness of a combination of adenoviral COVID-19 vaccines with a second dose of mRNA vaccines. This study aims to evaluate the antibody response to the SARS-CoV-2 spike protein 25 weeks after vaccination with mRNA-1273 after a first dose of ChAdOx1. A cross-sectional study was conducted collecting sociodemographic data, clinical characteristics, and serological data from among the general population. Antibody levels were expressed as binding antibody units (BAU) per mL (cutoff = 33.8 BAU\/mL). Linear regression models were used to assess the relationship between the subjects\u2019 characteristics and anti-SARS-CoV-2 antibody levels. A total of 229 participants were followed up after a median time of 173 days. The overall anti-SARS-CoV-2 IgG antibody titer was 729.0 BAU\/mL. The multivariable analysis showed that the only factor associated with anti-SARS-CoV-2 IgG levels was the BMI (p = 0.007), with decreases within the healthy range weight and increases in under- or overweight people. Our results support the use of heterologous COVID-19 vaccination regimens, as they can guarantee a sustained immune antibody response. More studies are needed to understand the link between BMI and body composition and the immune response to COVID-19 vaccinations.<\/jats:p>","DOI":"10.3390\/vaccines10081241","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:15:26Z","timestamp":1659485726000},"page":"1241","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune Response of a Heterologous mRNA-1273 Second-Dose Immunization after a First Dose of ChadOx1 against SARS-CoV-2: A Cross-Sectional Study"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7919-2927","authenticated-orcid":false,"given":"Beatrice","family":"Albanesi","sequence":"first","affiliation":[{"name":"Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8095-5461","authenticated-orcid":false,"given":"Alessandro","family":"Godono","sequence":"additional","affiliation":[{"name":"Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8601-1899","authenticated-orcid":false,"given":"Rosanna Irene","family":"Comoretto","sequence":"additional","affiliation":[{"name":"Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Casabona","sequence":"additional","affiliation":[{"name":"Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliano","family":"Curoso","sequence":"additional","affiliation":[{"name":"Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano Victor","family":"Leone","sequence":"additional","affiliation":[{"name":"Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00f2","family":"Milanesio","sequence":"additional","affiliation":[{"name":"Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilenia","family":"Mirra","sequence":"additional","affiliation":[{"name":"Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Montrucchio","sequence":"additional","affiliation":[{"name":"Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizia","family":"Pittaluga","sequence":"additional","affiliation":[{"name":"Microbiology and Virology Unit, Citt\u00e0 della Salute e della Scienza di Torino University Hospital, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Cavallo","sequence":"additional","affiliation":[{"name":"Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-2973","authenticated-orcid":false,"given":"Marco","family":"Clari","sequence":"additional","affiliation":[{"name":"Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catalina","family":"Ciocan","sequence":"additional","affiliation":[{"name":"Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e068302","DOI":"10.1136\/bmj-2021-068302","article-title":"Effectiveness of public health measures in reducing the incidence of COVID-19, SARS-CoV-2 transmission, and COVID-19 mortality: Systematic review and meta-analysis","volume":"375","author":"Talic","year":"2021","journal-title":"BMJ"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"106054","DOI":"10.1016\/j.ijantimicag.2020.106054","article-title":"Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): A global pandemic and treatment strategies","volume":"56","author":"Sharma","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(21)00085-4","article-title":"The European Medicines Agency\u2019s EU conditional marketing authorisations for COVID-19 vaccines","volume":"397","author":"Cavaleri","year":"2021","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"753319","DOI":"10.3389\/fimmu.2021.753319","article-title":"Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol","volume":"12","author":"Sablerolles","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/infdis\/jiy639","article-title":"Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal","volume":"219","author":"Venkatraman","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): A single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41586-021-04120-y","article-title":"Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination","volume":"600","author":"Pozzetto","year":"2021","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103761","DOI":"10.1016\/j.ebiom.2021.103761","article-title":"Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants","volume":"75","author":"Gross","year":"2022","journal-title":"EBioMedicine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jinf.2022.01.038","article-title":"Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England","volume":"84","author":"Westrop","year":"2022","journal-title":"J. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S2213-2600(21)00357-X","article-title":"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: A prospective cohort study","volume":"9","author":"Hillus","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): A multicentre, open-label, randomised, controlled, phase 2 trial","volume":"398","author":"Borobia","year":"2021","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10238-021-00771-3","article-title":"Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination","volume":"22","author":"Firinu","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1056\/NEJMc2110716","article-title":"Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination","volume":"385","author":"Normark","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Gram, M.A., Nielsen, J., Schelde, A.B., Nielsen, K.F., Moustsen-Helms, I.R., Sorensen, A.K.B., Valentiner-Branth, P., and Emborg, H.D. (2021). Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study. PLoS Med., 18.","DOI":"10.1371\/journal.pmed.1003874"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Fabricius, D., Ludwig, C., Scholz, J., Rode, I., Tsamadou, C., Jacobsen, E.M., Winkelmann, M., Grempels, A., Lotfi, R., and Janda, A. (2021). mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects. Vaccines, 9.","DOI":"10.3390\/vaccines9080918"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination","volume":"27","author":"Schmidt","year":"2021","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/S0140-6736(21)01115-6","article-title":"Heterologous prime-boost COVID-19 vaccination: Initial reactogenicity data","volume":"397","author":"Shaw","year":"2021","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"taab191","DOI":"10.1093\/jtm\/taab191","article-title":"Heterologous prime-boost strategies for COVID-19 vaccines","volume":"29","author":"Sapkota","year":"2021","journal-title":"J. Travel. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Guiomar, R., Santos, A.J., Melo, A.M., Costa, I., Matos, R., Rodrigues, A.P., Kislaya, I., Silva, A.S., Roque, C., and Nunes, C. (2022). Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination. Vaccines, 10.","DOI":"10.3390\/vaccines10020154"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Costa, C., Migliore, E., Galassi, C., Scozzari, G., Ciccone, G., Coggiola, M., Pira, E., Scarmozzino, A., La Valle, G., and Cassoni, P. (2022). Factors Influencing Level and Persistence of Anti SARS-CoV-2 IgG after BNT162b2 Vaccine: Evidence from a Large Cohort of Healthcare Workers. Vaccines, 18.","DOI":"10.3390\/vaccines10030474"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cca.2021.09.022","article-title":"Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy","volume":"523","author":"Raposo","year":"2021","journal-title":"Clin. Chim. Acta"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.humimm.2012.02.023","article-title":"Association between the human immune response and body mass index","volume":"73","author":"Ilavska","year":"2012","journal-title":"Hum. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cmi.2017.02.013","article-title":"Body mass index and the risk of infection\u2014From underweight to obesity","volume":"24","author":"Dobner","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1001\/jama.2009.1583","article-title":"Factors Associated With Death or Hospitalization Due to Pandemic 2009 Influenza A(H1N1) Infection in California","volume":"302","author":"Louie","year":"2009","journal-title":"JAMA-J. Am. Med. Assoc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1016\/j.vaccine.2006.04.016","article-title":"Hepatitis A\/B vaccination of adults over 40 years old: Comparison of three vaccine regimens and effect of influencing factors","volume":"24","author":"Chlibek","year":"2006","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0264-410X(96)00310-6","article-title":"The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults","volume":"15","author":"Reuman","year":"1997","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Perez-Perez, A., Sanchez-Jimenez, F., Vilarino-Garcia, T., and Sanchez-Margalet, V. (2020). Role of Leptin in Inflammation and Vice Versa. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165887"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3389\/fimmu.2018.01055","article-title":"Changes in Nutritional Status impact immune Cell Metabolism and Function","volume":"9","author":"Alwarawrah","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Bates, J.T., Farmer, A.P., Bierdeman, M.A., Ederer, D.R., Carney, L.S., Montgomery, D.D., Lirette, S.T., and Marshall, G.D. (2022). IgG Antibody Response to the Pfizer BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers with Healthy Weight, Overweight, and Obesity. Vaccines, 10.","DOI":"10.3390\/vaccines10040512"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100928","DOI":"10.1016\/j.eclinm.2021.100928","article-title":"Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine","volume":"36","author":"Pellini","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.numecd.2019.01.009","article-title":"Body mass index stratification in hospitalized Italian adults with congenital heart disease in relation to complexity, diagnosis, sex and age","volume":"29","author":"Malavazos","year":"2019","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/oby.23417","article-title":"Sex-associated differences between BMI and SARS-CoV-2 antibody titers following the BNT162b2 vaccine","volume":"30","author":"Yamamoto","year":"2022","journal-title":"Obesity"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.vaccine.2021.02.047","article-title":"Sex-specific effects of age and body mass index on antibody responses to seasonal influenza vaccines in healthcare workers","volume":"40","author":"Kuo","year":"2022","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Pellini, R., Venuti, A., Pimpinelli, F., Abril, E., Blandino, G., Campo, F., Conti, L., De Virgilio, A., De Marco, F., and Di Domenico, E.G. (medRXiv, 2021). Obesity may hamper Sars-CoV-2 vaccine immunogenicity, medRXiv, pre-print.","DOI":"10.1101\/2021.02.24.21251664"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/8\/1241\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:01:30Z","timestamp":1760140890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/8\/1241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["vaccines10081241"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10081241","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2022,8,2]]}}}